Murine CD8+ T cell cytotoxicity against schistosomula induced by inoculation of schistosomal 22.6/26GST coupled Sepharose 4B beads

Highlights ► DCs cross-present 22.6/26GST molecule-coupled Sepharose 4B beads to CD8+ T cells. ► The cross-presentation is TAP-independent. ► CD8+ T cells from particulate antigen-immunized mice kill schistosomula in vitro . ► Schistosomula acquired MHC I molecular from the host and became the cytot...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2012-03, Vol.30 (14), p.2440-2447
Main Authors: Zhou, Ying, Zhang, Hui, Sun, Xin-Juan, Zheng, Dan, Liang, Yue-Jin, Luo, Jie, Wang, Yong, Zhang, Zhao-Song
Format: Article
Language:English
Subjects:
agarose
Allergy and Immunology
Animals
antigen presentation
Antigen Presentation - immunology
antigens
Antigens, Helminth - administration & dosage
Antigens, Helminth - immunology
blood serum
CD8+T cells
Chemotherapy
Cross presentation
Cytotoxicity
Cytotoxicity, Immunologic - immunology
dendritic cells
Dendritic Cells - immunology
Eggs
Female
Freund's Adjuvant
Helminth Proteins - immunology
Immunization
Infections
Lymphocytes
Mice
Mice, Inbred BALB C
monitoring
Proteins
Public health
Schistosoma japonicum
Schistosoma japonicum - immunology
schistosomiasis
Schistosomiasis - immunology
Schistosomiasis - prevention & control
schistosomula
Sepharose - chemistry
Sepharose 4B
Studies
T-Lymphocytes, Cytotoxic - immunology
Tropical diseases
Vaccines
Vaccines - immunology
Worms
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights ► DCs cross-present 22.6/26GST molecule-coupled Sepharose 4B beads to CD8+ T cells. ► The cross-presentation is TAP-independent. ► CD8+ T cells from particulate antigen-immunized mice kill schistosomula in vitro . ► Schistosomula acquired MHC I molecular from the host and became the cytotoxic targets. ► Worm burdens decreased in particulate antigen-immunized mice after infection.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2012.01.068